肥胖中黑皮质素4受体通路功能障碍:以MC4R激动剂治疗为目标的患者分层
该研究通过流行病学分析预测美国携带POMC、PCSK1、LEPR双等位基因功能丧失变异的人数,并分析这些变异负荷与BMI的关联。结果预测约650例α-MSH/POMC、8500例PCSK1和3600例LEPR纯合或复合杂合个体,累计超过12800例MC4R通路缺陷肥胖患者;携带两个及以上LoF等位基因者比非携带者或单基因杂合携带者BMI更高。
要点
- 预测美国约12800例MC4R通路缺陷肥胖患者,多数尚未被基因诊断。
- POMC、PCSK1、LEPR双等位基因LoF变异可导致早发性严重肥胖。
- 两个及以上LoF等位基因者BMI高于非携带者或单基因杂合携带者。
核心结论
- MC4R通路双等位基因LoF变异患者数量可能被低估,基因分层有助于确定MC4R激动剂治疗研究人群。
研究设计与样本
- 对POMC、PCSK1和LEPR基因已知及预测LoF变异的综合流行病学分析,并检测不同人群中BMI与LoF突变负荷的关联。
主要发现
- 预测美国约650例α-MSH/POMC、8500例PCSK1和3600例LEPR纯合及复合杂合个体,累计超过12800例MC4R通路缺陷肥胖患者。
- 纳入β-MSH/POMC、PCSK1 N221D和PCSK1 LoF变异T640A等较少见变异后,上述估计值增加。
- 在一个或多个MC4R通路基因中携带两个及以上LoF等位基因的个体,其BMI高于非携带者或仅一个基因缺陷的杂合LoF携带者。
关键数值与推荐
- POMC、PCSK1、LEPR基因双等位基因LoF变异定义为MC4R通路缺陷;两个及以上LoF等位基因与更高BMI相关。
临床怎么用
- 对早发性严重肥胖患者可考虑MC4R通路基因检测,以识别可能从MC4R激动剂(如setmelanotide)治疗研究中获益的亚群。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The hypothalamic melanocortin 4 receptor (MC4R) pathway serves a critical role in regulating body weight. Loss of function (LoF) mutations in the MC4R pathway, including mutations in the pro-opiomelanocortin (POMC), prohormone convertase 1 (PCSK1), leptin receptor (LEPR), or MC4R genes, have been shown to cause early-onset severe obesity. METHODS: Through a comprehensive epidemiological analysis of known and predicted LoF variants in the POMC, PCSK1, and LEPR genes, we sought to estimate the number of US individuals with biallelic MC4R pathway LoF variants. RESULTS: We predict ~650 α-melanocyte-stimulating hormone (MSH)/POMC, 8500 PCSK1, and 3600 LEPR homozygous and compound heterozygous individuals in the United States, cumulatively enumerating >12,800 MC4R pathway-deficient obese patients. Few of these variants have been genetically diagnosed to date. These estimates increase when we include a small subset of less rare variants: β-MSH/POMC,PCSK1 N221D, and a PCSK1 LoF variant (T640A). To further define the MC4R pathway and its potential impact on obesity, we tested associations between body mass index (BMI) and LoF mutation burden in the POMC, PCSK1, and LEPR genes in various populations. We show that the cumulative allele burden in individuals with two or more LoF alleles in one or more genes in the MC4R pathway are predisposed to a higher BMI than noncarriers or heterozygous LoF carriers with a defect in only one gene. CONCLUSIONS: Our analysis represents a genetically rationalized study of the hypothalamic MC4R pathway aimed at genetic patient stratification to determine which obese subpopulations should be studied to elucidate MC4R agonist (e.g., setmelanotide) treatment responsiveness.
引用
- Ayers KL, Glicksberg BS, Garfield AS, et al. Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment. J Clin Endocrinol Metab. 2018. PMID: 29726959. doi:10.1210/jc.2018-00258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。